Key result
Blocking the EP3 receptor with DG-041 reduced platelet aggregation without significantly altering cutaneous bleeding time in healthy patients, and inhibited atherothrombosis in mice.
Why the study?
Does DG-041 reduce thrombosis without impairing haemostasis in murine models and healthy patients?
Population
Murine models of thrombosis and atherosclerosis, human atherosclerotic plaques and blood, and healthy human…
Design
Preclinical
Authors
Loading...
EP3 blockade may enable antithrombotic effects without bleeding liability; leaves open confirmation in cardiovascular patients.
Does DG-041 reduce thrombosis without impairing haemostasis in murine models and healthy patients?
Blocking the EP3 receptor with DG-041 reduces thrombosis and enhances clopidogrel efficacy without increasing bleeding risk in preclinical models and healthy volunteers.
Tilly et al. (2013) studied Healthy volunteers and murine models. DG-041 was evaluated on Platelet aggregation and cutaneous bleeding time. Blocking the EP3 receptor with DG-041 reduced platelet aggregation without significantly altering cutaneous bleeding time in healthy patients, and inhibited atherothrombosis in mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: